ci 988 has been researched along with sorbitol in 2 studies
| Studies (ci 988) | Trials (ci 988) | Recent Studies (post-2010) (ci 988) | Studies (sorbitol) | Trials (sorbitol) | Recent Studies (post-2010) (sorbitol) |
|---|---|---|---|---|---|
| 147 | 8 | 14 | 6,530 | 359 | 946 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hökfelt, T; Horwell, DC; Hughes, J; Wiesenfeld-Hallin, Z; Xu, XJ | 1 |
| Boden, P; Costall, B; Domeney, A; Horwell, DC; Hughes, J; Hunter, JC; Kelly, E; Pinnock, RD; Woodruff, GN | 1 |
2 other study(ies) available for ci 988 and sorbitol
| Article | Year |
|---|---|
PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.
Topics: Analgesics; Animals; Cholecystokinin; Drug Synergism; Female; Galanin; Indoles; Injections, Spinal; Kinetics; Male; Meglumine; Morphine; Naloxone; Nociceptors; Pain; Peptides; Rats; Rats, Inbred Strains; Receptors, Cholecystokinin; Reflex; Sorbitol; Spinal Cord; Time Factors | 1990 |
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
Topics: Animals; Anti-Anxiety Agents; Binding, Competitive; Callitrichinae; Cell Membrane; Cerebral Cortex; Cholecystokinin; Electrophysiology; Humans; Indoles; Kinetics; Meglumine; Mice; Pancreas; Rats; Receptors, Cholecystokinin; Social Behavior; Sorbitol; Ventromedial Hypothalamic Nucleus | 1990 |